Tradestie Institutional Equity Comparison Engine

FDMT vs ALXO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALXO Overall Edge

ALXO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ALX Oncology Holdings Inc. Common Stock (ALXO) driven by superior Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus ALXO at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against ALXO sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FDMT N/M vs ALXO N/M Fwd P/E
Growth & Margin Winner ALXO
Op Margin -222.7% vs 0.0% ยท YoY +4505.6% vs -100.0%
Momentum & Technical Winner FDMT
1Y +13.3% vs -22.5% ยท 52W Pos 47% vs 5%
Options & Structure Winner ALXO
BREAKDOWN (10th %ile IV) vs BREAKDOWN (20th %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
ALXO NASDAQ
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$0.95
-9.07% 1D
Market Cap $149.3M
1M Return -10.78%
1Y Return -22.48%
Forward P/E N/M
Unified AI Score
61.5 / 100 BUY
Tech 50.0 Fund 60.0 Flow 68.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% ALXO -22.48% Spread: +35.81 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FDMT Revenue ALXO Revenue FDMT Op. Margin ALXO Op. Margin Margin Edge
FY2018 N/A $0M N/A -662.0% ALXO
FY2019 $10M $0M -729.4% -400.0% ALXO
FY2020 $10M $0M -424.0% -3694.0% FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M N/A -3516.5% N/A FDMT
FY2023 $20M N/A -544.6% N/A FDMT
FY2024 $0M N/A -507678.4% N/A FDMT
FY2025 $90M N/A -187.2% N/A FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (5) vs ALXO (3)
Institutional Metric FDMT ALXO Criterion Row Winner
Market Capitalization Scale $669.3M $149.3M Larger Scale FDMT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +4505.6% -100.0% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% 0.0% Higher Margin ALXO
Net Profit Margin Profitability -208.6% 0.0% Higher Margin ALXO
Return on Equity (ROE) Capital Efficiency -56.7% -80.7% Higher ROE FDMT
52-Week Range Position Momentum 47% ($7โ€“$17) 5% ($1โ€“$3) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 1.46ฮฒ ยท 117% Vol Lower Realized Risk FDMT
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite ALXO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs ALXO Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALXO BREAKDOWN
93d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live ALXO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor ALXO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.